Abciximab (Synonyms: C7E3) |
Catalog No.GC65597
One-Click Copy Product Info
|
Abciximab, a chimeric (murine/human) monoclonal antibody fragment (c7E3 Fab), is a glycoprotein IIb/IIIa antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 143653-53-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Abciximab, a chimeric (murine/human) monoclonal antibody fragment (c7E3 Fab), is a glycoprotein IIb/IIIa antagonist [1]. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors [2]. Abciximab has been used to destabilize coronary thrombi and disperse mural thrombi [3].
In vitro, Abciximab treatment for 24 hours significantly inhibited the chemotaxis and invasion of human coronary smooth muscle cells (hcSMCs), with IC50 value of 33.0μg/ml and 0.5μg/ml, respectively [4]. Treatment with 10μg/ml Abciximab for 30 minutes decreased generation of new thrombin on both collagen-coated platelets and clot-adherent platelet [5].
References:
[1] Tcheng J E, Kereiakes D J, Lincoff A M, et al. Abciximab readministration: results of the ReoPro Readministration Registry[J]. Circulation, 2001, 104(8): 870-875.
[2] Ibbotson T, McGavin J K, Goa K L. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation[J]. Drugs, 2003, 63(11): 1121-1163.
[3] Marciniak Jr S J, Mascelli M A, Furman M I, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates[J]. Thrombosis and haemostasis, 2002, 87(06): 1020-1025.
[4] Blindt R, Bosserhoff A K, Zeiffer U, et al. Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells[J]. Journal of Molecular and Cellular Cardiology, 2000, 32(12): 2195-2206.
[5] Ilveskero S, Lassila R. Abciximab inhibits procoagulant activity but not the release reaction upon collagen-or clot-adherent platelets[J]. Journal of Thrombosis and Haemostasis, 2003, 1(4): 805-813.
| Cell experiment [1]: | |
Cell lines | Human coronary smooth muscle cells (hcSMCs) |
Preparation Method | The hcSMCs were cultivated in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100units/ml penicillin, and 100mg/ml streptomycin at 37°C in an incubator with 5% CO2. Cells were seeded in a 96-well plate at a density of 1×104 cells/well for 24h. Cells were treated with Abciximab at a range of concentrations (0, 1, 10, and 50μM). After 24h of treatment, the cell migration and invasion were determined. |
Reaction Conditions | 0, 1, 10, and 50μM; 24h |
Applications | Abciximab treatment inhibited cell migration and invasion in hcSMCs in a dose-dependent manner. |
References: | |
| Cas No. | 143653-53-6 | SDF | |
| Synonyms | C7E3 | ||
| Formula | M.Wt | ||
| Solubility | Storage | Store at -80°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >95.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)